Literature DB >> 26908728

Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years.

Hung Fu Tseng1, Rafael Harpaz2, Yi Luo1, Craig M Hales2, Lina S Sy1, Sara Y Tartof1, Stephanie Bialek2, Rulin C Hechter1, Steven J Jacobsen1.   

Abstract

Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated with vaccination at each year following vaccination were estimated by Cox regression model. The effectiveness of HZ vaccine decreased from 68.7% (95% CI, 66.3%-70.9%) in the first year to 4.2% (95% CI, -24.0% to 25.9%) in the eighth year. This rapid decline in effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  adult vaccination; herpes zoster; shingles; varicella zoster virus

Mesh:

Substances:

Year:  2016        PMID: 26908728     DOI: 10.1093/infdis/jiw047

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Role for the αV Integrin Subunit in Varicella-Zoster Virus-Mediated Fusion and Infection.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

2.  Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study.

Authors:  Mélanie Drolet; Zhou Zhou; Chantal Sauvageau; Philippe DeWals; Vladimir Gilca; Rachid Amini; Élodie Bénard; Marc Brisson
Journal:  CMAJ       Date:  2019-08-26       Impact factor: 8.262

3.  Clinical and economic impact of herpes zoster vaccination in elderly in Italy.

Authors:  Sara Boccalini; Cristiano Alicino; Domenico Martinelli; Angela Bechini; Emilia Tiscione; Barbara Pellizzari; Rosa Prato; Giancarlo Icardi; Stefania Iannazzo; Paolo Bonanni
Journal:  Hum Vaccin Immunother       Date:  2016-12-07       Impact factor: 3.452

4.  Herpes Zoster Vaccine: Time for a Boost?

Authors:  Krishna P Reddy
Journal:  J Gen Intern Med       Date:  2017-02       Impact factor: 5.128

5.  Clinical Usage of the Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su): Revaccination of Recipients of Live Attenuated Zoster Vaccine and Coadministration With a Seasonal Influenza Vaccine.

Authors:  Michael N Oxman; Ruth Harbecke; David M Koelle
Journal:  J Infect Dis       Date:  2017-12-12       Impact factor: 5.226

6.  Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).

Authors:  Laura P Hurley; Mandy A Allison; Kathleen L Dooling; Sean T O'Leary; Lori A Crane; Michaela Brtnikova; Brenda L Beaty; Jessica A Allen; Angela Guo; Megan C Lindley; Allison Kempe
Journal:  Vaccine       Date:  2018-10-26       Impact factor: 3.641

7.  The Glycoprotein B Cytoplasmic Domain Lysine Cluster Is Critical for Varicella-Zoster Virus Cell-Cell Fusion Regulation and Infection.

Authors:  Edward Yang; Ann M Arvin; Stefan L Oliver
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

8.  Th1 memory differentiates recombinant from live herpes zoster vaccines.

Authors:  Myron J Levin; Miranda E Kroehl; Michael J Johnson; Andrew Hammes; Dominik Reinhold; Nancy Lang; Adriana Weinberg
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

9.  Longterm Effectiveness of Herpes Zoster Vaccine among Patients with Autoimmune and Inflammatory Diseases.

Authors:  Huifeng Yun; Fenglong Xie; John W Baddley; Kevin Winthrop; Kenneth G Saag; Jeffrey R Curtis
Journal:  J Rheumatol       Date:  2017-03-15       Impact factor: 4.666

10.  The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and Varicella-Zoster Virus-Specific T Cell Immunity.

Authors:  Adriana Weinberg; Lei Pang; Michael J Johnson; Yupanqui Caldas; Alice Cho; Adriana Tovar-Salazar; Jennifer Canniff; Kenneth E Schmader; Zoran Popmihajlov; Myron J Levin
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.